These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 14681512)

  • 1. Medical management of benign prostatic hyperplasia--are two drugs better than one?
    Vaughan ED
    N Engl J Med; 2003 Dec; 349(25):2449-51. PubMed ID: 14681512
    [No Abstract]   [Full Text] [Related]  

  • 2. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride in benign prostatic hyperplasia.
    Verhamme KM; Bosch RJ; Sturkenboom MC
    N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034
    [No Abstract]   [Full Text] [Related]  

  • 4. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
    MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
    [No Abstract]   [Full Text] [Related]  

  • 5. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug treatment of benign prostatic hyperplasia].
    Schmid HP
    Praxis (Bern 1994); 1995 Sep; 84(39):1061-2. PubMed ID: 7481307
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the best medical treatment for benign prostate hyperplasia?
    Evans MF; Frank J
    Can Fam Physician; 1997 Jun; 43():1073-4. PubMed ID: 9189295
    [No Abstract]   [Full Text] [Related]  

  • 8. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
    MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising the medical management of benign prostatic hyperplasia.
    McDermott T
    Br J Clin Pract; 1997 Mar; 51(2):116-8. PubMed ID: 9158256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of benign prostatic hyperplasia.
    Samkange C; Bhagat K
    Cent Afr J Med; 2000 Aug; 46(8):224-8. PubMed ID: 11317596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment as an alternative to surgery in the management of benign prostatic hypertrophy.
    Bredin HC
    Ir Med J; 1996; 89(3):86, 88. PubMed ID: 8707527
    [No Abstract]   [Full Text] [Related]  

  • 13. [The tested combination is recommended. Are 5-alpha reductase inhibitors interchangeable?].
    MMW Fortschr Med; 2003 Jul; 145(27-28):59. PubMed ID: 14587194
    [No Abstract]   [Full Text] [Related]  

  • 14. Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.
    Nehra A
    BJU Int; 2005 Aug; 96(3):237-43. PubMed ID: 16042709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medical therapy of benign prostatic hyperplasia].
    Altarac S
    Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of benign prostatic hyperplasia.
    Walsh PC
    N Engl J Med; 1996 Aug; 335(8):586-7. PubMed ID: 8678937
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
    Hausmann R; Thalmann G; Reich O; Steif CG
    Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cost-effectiveness aspects of benign prostatic hyperplasia (BPH) therapy].
    Lopatkin NA; Ziborova IV; Sivkov AV; Apolikhin OI
    Urol Nefrol (Mosk); 1999; (1):22-6. PubMed ID: 11149340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked].
    MMW Fortschr Med; 2003 Jul; 145(27-28):58-9. PubMed ID: 14587193
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical management of benign prostatic hypertrophy.
    Geller J
    Compr Ther; 1994; 20(12):682-7. PubMed ID: 7533690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.